Biogen Confirms US Approval for TECFIDERA
March 27, 2013 at 16:12 PM EDT
Today Biogen Idec (NASDAQ: BIIB ) announced that the U.S. Food and Drug Administration (FDA) has approved TECFIDERA™ (dimethyl fumarate), a new first-line oral treatment for people with relapsing forms of multiple sclerosis (MS). Biogen Idec will make this oral capsule available to people living with MS in the
